$280,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to CMMI drug pricing Most Favored Nation drug pricing; Issues related to CMMI drug pricing"
You can find more data on corporate lobbying on Quiver Quantitative.
MDGL Insider Trading Activity
MDGL insiders have traded $MDGL stock on the open market 244 times in the past 6 months. Of those trades, 54 have been purchases and 190 have been sales.
Here’s a breakdown of recent trading of $MDGL stock by insiders over the last 6 months:
- PAUL A FRIEDMAN has made 0 purchases and 67 sales selling 225,580 shares for an estimated $91,113,997.
- BROS. ADVISORS LP BAKER has made 54 purchases buying 165,683 shares for an estimated $61,921,024 and 0 sales.
- REBECCA TAUB has made 0 purchases and 52 sales selling 86,001 shares for an estimated $37,654,339.
- KENNETH BATE has made 0 purchases and 17 sales selling 26,575 shares for an estimated $11,679,362.
- WILLIAM JOHN SIBOLD (President and CEO) has made 0 purchases and 4 sales selling 17,295 shares for an estimated $7,672,313.
- RICHARD S LEVY has made 0 purchases and 14 sales selling 8,500 shares for an estimated $4,428,197.
- MARDI DIER (EVP and CFO) has made 0 purchases and 15 sales selling 4,173 shares for an estimated $2,413,416.
- CAROLE HUNTSMAN (Chief Commercial Officer) has made 0 purchases and 11 sales selling 1,958 shares for an estimated $1,082,986.
- SHANNON T KELLEY (General Counsel) has made 0 purchases and 10 sales selling 1,996 shares for an estimated $823,799.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
MDGL Hedge Fund Activity
We have seen 189 institutional investors add shares of MDGL stock to their portfolio, and 150 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 397,076 shares (+5381.2%) to their portfolio in Q3 2025, for an estimated $182,122,878
- JANUS HENDERSON GROUP PLC removed 349,063 shares (-15.9%) from their portfolio in Q3 2025, for an estimated $160,101,235
- UBS GROUP AG removed 288,371 shares (-57.0%) from their portfolio in Q3 2025, for an estimated $132,264,242
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 287,663 shares (-76.5%) from their portfolio in Q3 2025, for an estimated $131,939,511
- GOLDMAN SACHS GROUP INC added 196,260 shares (+103.4%) to their portfolio in Q3 2025, for an estimated $90,016,611
- PAULSON & CO. INC. removed 182,000 shares (-8.7%) from their portfolio in Q3 2025, for an estimated $83,476,120
- BAKER BROS. ADVISORS LP added 165,683 shares (+8.4%) to their portfolio in Q3 2025, for an estimated $75,992,164
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
MDGL Analyst Ratings
Wall Street analysts have issued reports on $MDGL in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citizens issued a "Market Outperform" rating on 01/20/2026
- HC Wainwright & Co. issued a "Buy" rating on 11/21/2025
- Oppenheimer issued a "Outperform" rating on 11/20/2025
- Truist Securities issued a "Buy" rating on 11/19/2025
- Canaccord Genuity issued a "Buy" rating on 11/13/2025
- Cantor Fitzgerald issued a "Overweight" rating on 11/05/2025
- Piper Sandler issued a "Overweight" rating on 10/15/2025
To track analyst ratings and price targets for MDGL, check out Quiver Quantitative's $MDGL forecast page.
MDGL Price Targets
Multiple analysts have issued price targets for $MDGL recently. We have seen 12 analysts offer price targets for $MDGL in the last 6 months, with a median target of $603.5.
Here are some recent targets:
- Jonathan Wolleben from Citizens set a target price of $745.0 on 01/20/2026
- Yasmeen Rahimi from Piper Sandler set a target price of $900.0 on 12/19/2025
- William Woods from B. Riley Securities set a target price of $670.0 on 12/11/2025
- Andrew S. Fein from HC Wainwright & Co. set a target price of $620.0 on 11/21/2025
- Jay Olson from Oppenheimer set a target price of $650.0 on 11/20/2025
- Srikripa Devarakonda from Truist Securities set a target price of $640.0 on 11/19/2025
- Edward Nash from Canaccord Genuity set a target price of $587.0 on 11/13/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
